Clear cell RCC is the most common type of RCC and is rich in vascular networks induced by dysregulation of the VHL/HIF pathway, which provides a scientific rationale for developing VEGFR‐focused multikinase inhibitors (sorafenib, sunitinib, pazopanib, axitinib, cabozantinib, lenvatinib, and tivozanib) in this tumor type.475, 674, 676, 677. This evidence concerns the gene VHL and renal cell carcinoma.